Population-Impact Model Estimating Clinical and Economic Outcomes Associated with Emicizumab in People with Moderate or Severe Hemophilia a in the US
Journal of Blood Medicine · 2026-11 · Volume 17 · 1-12
DOI: 10.2147/jbm.s619045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Blood Medicine, 2026-11. Verfasst von Janet S Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, CA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, CA, USA.
Zitieren
APA
Lee, J. S., El Moustaid, F., & Lee, L. Y. (2026). Population-Impact Model Estimating Clinical and Economic Outcomes Associated with Emicizumab in People with Moderate or Severe Hemophilia a in the US. Journal of Blood Medicine, Volume 17, 1-12. https://doi.org/10.2147/jbm.s619045
Vancouver
Lee JS, El Moustaid F, Lee LY. Population-Impact Model Estimating Clinical and Economic Outcomes Associated with Emicizumab in People with Moderate or Severe Hemophilia a in the US. Journal of Blood Medicine. 2026;Volume 17:1-12. doi:10.2147/jbm.s619045
BibTeX
@article{Lee2026,
author = {Lee, Janet S and El Moustaid, Fadoua and Lee, Lucy Y},
title = {Population-Impact Model Estimating Clinical and Economic Outcomes Associated with Emicizumab in People with Moderate or Severe Hemophilia a in the US},
journal = {Journal of Blood Medicine},
year = {2026},
volume = {Volume 17},
pages = {1--12},
doi = {10.2147/jbm.s619045}
}
EUVIMED